Intersect ENT has agreed to acquire Fiagon AG Medical Technologies – Click here to learn more

LOCALIZED STEROID-RELEASING TECHNOLOGY

Intersect ENT’s core technology is its bioabsorbable drug release platform. The current portfolio of sinus implants is designed to provide mechanical support and localized drug delivery.

Instructions For Use
PROPEL: US | EU
PROPEL Mini: US | EU
PROPEL Contour: US

VISIT PROPELOPENS.COM

Prescribing Information
SINUVA: US

VISIT SINUVA.COM

The above-identified implants, delivery systems, and/or the use of the above-identified implants/delivery systems in a method may be covered by one or more U.S. and/or foreign patents, found at intersectent.com/patents